Improving cancer treatment by targeting a specific protein in immune cells
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy
This study is looking at how blocking a specific protein called PIM-2 might help improve cancer treatments for people with acute T-cell leukemia by making the immune system's T-cells better at fighting tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project ID | NIH-11037906 on NIH RePORTER |
What this research studies
This research investigates how targeting the PIM-2 kinase protein can enhance the effectiveness of cancer immunotherapy, particularly in treating acute T-cell leukemia. The approach involves studying the role of PIM-2 in T-cell responses, using genetically modified mice to understand how its absence affects the immune system's ability to fight tumors. By blocking or removing PIM-2, researchers aim to boost the anti-tumor activity of T-cells, potentially leading to better outcomes for patients undergoing immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute T-cell leukemia who are seeking innovative treatment options.
Not a fit: Patients with other types of cancer or those who do not have acute T-cell leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with acute T-cell leukemia.
How similar studies have performed: Previous research has shown promising results in targeting similar immune pathways, suggesting that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
Milwaukee, United States
- Medical College of Wisconsin — Milwaukee, United States (Active)
Researchers
- Principal investigator: Yu, Xue-Zhong — Medical College of Wisconsin
- Study coordinator: Yu, Xue-Zhong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.